| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer
|
Lee, S.Y.
|
|
|
26 |
6 |
p. 1142-1148
|
artikel
|
| 2 |
A personalised medicine approach for ponatinib-resistant chronic myeloid leukaemia
|
Korfi, K.
|
|
|
26 |
6 |
p. 1180-1187
|
artikel
|
| 3 |
Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary
|
Morrison, V.A.
|
|
|
26 |
6 |
p. 1058-1068
|
artikel
|
| 4 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study
|
Roila, F.
|
|
|
26 |
6 |
p. 1248-1253
|
artikel
|
| 5 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer
|
Deplanque, G.
|
|
|
26 |
6 |
p. 1194-1200
|
artikel
|
| 6 |
Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
|
Woolf, D.K.
|
|
|
26 |
6 |
p. 1048-1057
|
artikel
|
| 7 |
Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making
|
Passaro, A.
|
|
|
26 |
6 |
p. 1270-1271
|
artikel
|
| 8 |
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
|
|
|
|
26 |
6 |
p. 1274
|
artikel
|
| 9 |
Determining the indications for post mastectomy radiotherapy: moving from 20th century clinical staging to 21st century biological criteria
|
Russell, N.S.
|
|
|
26 |
6 |
p. 1043-1044
|
artikel
|
| 10 |
Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse
|
Hartkopf, A.D.
|
|
|
26 |
6 |
p. 1155-1160
|
artikel
|
| 11 |
Does interim PET increase the value of ABVD in advanced-stage Hodgkin lymphoma?
|
Gallamini, A.
|
|
|
26 |
6 |
p. 1045-1047
|
artikel
|
| 12 |
Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial
|
Fontein, D.B.Y.
|
|
|
26 |
6 |
p. 1254-1262
|
artikel
|
| 13 |
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest
|
Cremolini, C.
|
|
|
26 |
6 |
p. 1188-1194
|
artikel
|
| 14 |
Editorial Board
|
|
|
|
26 |
6 |
p. ii-iii
|
artikel
|
| 15 |
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
|
Passardi, A.
|
|
|
26 |
6 |
p. 1201-1207
|
artikel
|
| 16 |
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
|
Davis, I.D.
|
|
|
26 |
6 |
p. 1118-1123
|
artikel
|
| 17 |
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG) †
|
Ravaud, A.
|
|
|
26 |
6 |
p. 1123-1128
|
artikel
|
| 18 |
Genetic lesions in diffuse large B-cell lymphomas
|
Testoni, M.
|
|
|
26 |
6 |
p. 1069-1080
|
artikel
|
| 19 |
Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing
|
Chung, C.H.
|
|
|
26 |
6 |
p. 1216-1223
|
artikel
|
| 20 |
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma
|
Izzedine, H.
|
|
|
26 |
6 |
p. 1128-1133
|
artikel
|
| 21 |
Integrative molecular profiling of routine clinical prostate cancer specimens
|
Grasso, C.S.
|
|
|
26 |
6 |
p. 1110-1118
|
artikel
|
| 22 |
Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data
|
Capocaccia, R.
|
|
|
26 |
6 |
p. 1263-1268
|
artikel
|
| 23 |
No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study
|
Nordenskjöld, A.E.
|
|
|
26 |
6 |
p. 1149-1154
|
artikel
|
| 24 |
Patients' preference and informed consent
|
Pumo, V.
|
|
|
26 |
6 |
p. 1269
|
artikel
|
| 25 |
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
|
Cheah, C.Y.
|
|
|
26 |
6 |
p. 1175-1179
|
artikel
|
| 26 |
Phase II study of interim PET–CT-guided response-adapted therapy in advanced Hodgkin's lymphoma
|
Ganesan, P.
|
|
|
26 |
6 |
p. 1170-1174
|
artikel
|
| 27 |
Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
|
Chiorean, E.G.
|
|
|
26 |
6 |
p. 1230-1237
|
artikel
|
| 28 |
Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer
|
Deutsch, E.
|
|
|
26 |
6 |
p. 1223-1229
|
artikel
|
| 29 |
Postoperative irinotecan in resected stage II–III rectal cancer: final analysis of the French R98 Intergroup trial †
|
Delbaldo, C.
|
|
|
26 |
6 |
p. 1208-1215
|
artikel
|
| 30 |
Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?
|
Conde-Estévez, D.
|
|
|
26 |
6 |
p. 1272
|
artikel
|
| 31 |
Prioritizing precision medicine for prostate cancer
|
Attard, G.
|
|
|
26 |
6 |
p. 1041-1042
|
artikel
|
| 32 |
Radiosensitization by BRAF inhibitor therapy—mechanism and frequency of toxicity in melanoma patients
|
Hecht, M.
|
|
|
26 |
6 |
p. 1238-1244
|
artikel
|
| 33 |
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
|
Jordan, K.
|
|
|
26 |
6 |
p. 1081-1090
|
artikel
|
| 34 |
Reply to the letter to the editor ‘Patients' preference and informed consent’ by Pumo et al.
|
Pivot, X.
|
|
|
26 |
6 |
p. 1269-1270
|
artikel
|
| 35 |
Reply to the letter to the editor ‘Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?’ by Conde-Estévez et al.
|
van Leeuwen, R.W.F.
|
|
|
26 |
6 |
p. 1272-1273
|
artikel
|
| 36 |
Survival in stage I–III breast cancer patients by surgical treatment in a publicly funded health care system
|
Fisher, S.
|
|
|
26 |
6 |
p. 1161-1169
|
artikel
|
| 37 |
Table of Contents
|
|
|
|
26 |
6 |
p. iv-vi
|
artikel
|
| 38 |
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
|
Mitchell, P.
|
|
|
26 |
6 |
p. 1134-1142
|
artikel
|
| 39 |
The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax)
|
Al-Batran, S.-E.
|
|
|
26 |
6 |
p. 1244-1248
|
artikel
|
| 40 |
The prevalence and outcomes of frailty in older cancer patients: a systematic review
|
Handforth, C.
|
|
|
26 |
6 |
p. 1091-1101
|
artikel
|
| 41 |
Visceral adiposity and colorectal adenomas: dose-response meta-analysis of observational studies
|
Keum, N.
|
|
|
26 |
6 |
p. 1101-1109
|
artikel
|
Tijdschrift beschrijving